The paradox of the evidence about invasive fungal infection prevention by Cortegiani, A. et al.
EDITORIAL Open Access
The paradox of the evidence about
invasive fungal infections prevention
Andrea Cortegiani*, Vincenzo Russotto, Santi Maurizio Raineri and Antonino Giarratano
Invasive fungal infections (IFIs) are characterized by
high morbidity and mortality in non-neutropenic critic-
ally ill patients. Attributable mortality due to Candida
spp. infections ranges from about 42 to 63 % [1, 2]. Data
from large observational and retrospective studies show
an association between early antifungal treatment and
improved survival [3, 4]. Updated clinical practice guide-
lines for the management of candidiasis have been recently
published [5].
In 2006, Playford et al. published a Cochrane system-
atic review investigating the use of antifungal agents for
prevention of IFIs in non-neutropenic critically ill
patients [6]. In that review, the outcome of proven IFI
was defined as a clinical illness consistent with the diag-
nosis and either histopathological evidence of IFI or a
positive fungal culture from one or more sterile site
specimens (including blood). Notably, funguria (as indi-
cated by a positive urine fungal culture), in the absence
of a complicated urinary tract infection, and fungal
esophagitis were classified not as IFIs but as superficial
fungal infections. The review included 12 studies and
1606 patients, and the use of antifungal agents was asso-
ciated with a mortality reduction of about 25 % and with
an IFI reduction of about 50 %. Recently, we updated
the original review by Playford et al., including 22 ran-
domized controlled trials (RCTs) and 2761 patients [7].
We modified the definition of the outcome-proven IFI
excluding positive culture of Candida spp. from the
respiratory tract, even in the presence of systemic or
respiratory signs of infection, and classifying it as
colonization instead of IFI. Untargeted antifungal treat-
ment, encompassing prophylactic, pre-emptive, and
empiric regimens [8], was not associated with a signifi-
cant mortality reduction (moderate-quality evidence).
However, antifungal agents reduced IFIs by about 45 %
with low-grade-quality evidence. From these data, three
clinical questions may arise.
1. How is it possible to observe a reduced
invasive fungal infection without any significant
survival benefit?
The original review included studies published before
2006 and only one multicenter study [9]. In the following
years, several multicenter studies have been published.
New molecules and approaches for untargeted antifungal
treatment were tested but without any survival benefit
[10–12]. The inclusion of multicenter studies improved
the overall quality of available evidence, increased the total
number of patients, and possibly diluted the original ef-
fect size on mortality. Additionally, it may be argued
that the care of critically ill patients improved in terms
of management and prevention of sepsis. This may have
led to a blunted effect of the reduction of IFIs on mortality.
Another possible explanation may rely on the recently de-
scribed suppressive immunophenotype of septic patients
with candidemia. From this perspective, it may be hypothe-
sized that, although an effective antifungal treatment led to
microbiological eradication and reduced fungal load and
incidence of IFIs, patients still die from the consequences
of their underlying impaired immunological function [13].
2. Is there an untargeted antifungal strategy or
an antifungal drug more effective than others?
Subanalyses did not show any survival benefit from the
use of either prophylactic or empiric treatment. No
effect was detected for azoles, echinocandins, absorbable,
or non-absorbable antifungals. Antifungal prophylaxis was
associated with a significant reduction of IFI, whereas em-
piric treatment was not [7]. Only one RCT evaluated the
pre-emptive approach and few patients were enrolled [14].
It may be argued that studies investigating empiric treat-
ment, defined as the administration of antifungals in pa-
tients with signs/symptoms of infections at risk for IFIs,
enrolled subjects with a more advanced disease process,
leading to lack of efficacy. Azoles were associated with a
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significant reduction of IFIs, whereas studies investigating
echinocandins did not show any significant benefit on
IFI reduction. Notably, the numbers of studies and in-
cluded patients were higher for the subanalyses of
prophylaxis and azoles. An ongoing multicenter RCT
will provide more data on the use of empiric treat-
ment with echinocandins [15].
3. Should clinicians administer antifungals prior
to definitive diagnosis of invasive fungal
infection?
According to the available evidence from RCTs, untar-
geted antifungal therapy may lead to a reduction of IFIs
without any survival benefit in non-neutropenic critically
ill patients. Physicians should evaluate, case by case, the
risks and benefits of the antifungal treatment after con-
sidering timing, risk factors, local microbiological epi-
demiology, and costs. Moreover, the extended use of
untargeted antifungal treatment may be associated with
increased resistance to these drugs [16]. Physicians
should be aware that evidence from the last Cochrane
review could not evaluate the relationship between
severity of illness and potential benefit of antifungal
treatment. There is a need for RCTs investigating the
effectiveness of pre-emptive antifungal approaches (i.e.,
surrogate marker-driven treatment).
To solve the paradox, future studies should also better
evaluate the pathophysiology of the IFI process in order
to answer the challenging question of whether critically
ill patients would die of or with IFIs.
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